VK2809
Lipid and metabolic disorders
Phase 2bActive
Key Facts
About Viking Therapeutics
Viking Therapeutics leverages its expertise in metabolism to develop innovative therapies for metabolic and endocrine disorders. The company's most advanced program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 trials for obesity, with promising Phase 2 data showing significant weight reduction. Viking is also developing VK2809 for lipid disorders and maintains a broader pipeline including VK0214 and VK5211, positioning itself as a key player in the competitive metabolic disease space.
View full company profile